Effects of exogenous somatotropin on whole-body glycemic response to insulin in young preruminant and ruminant lambs.
The purpose of this study was to determine the effects of exogenous recombinant bovine somatotropin (bST) treatment on whole-body glycemic responsiveness and sensitivity to exogenous insulin in preruminant and ruminant lambs. Twelve milk-fed (MF) and 12 ruminating (RUM) wether lambs weighing 20 +/- 0.6 kg were assigned to one of four treatment groups: MF control, MF plus bST, RUM control, and RUM plus bST. Lambs received a daily subcutaneous injection of 160 micrograms of sometribove (recombinant methionyl bST) bST/kg live weight or the equivalent volume of sterile water (control) for 10 d. The MF lambs had higher plasma insulin and nonessential fatty acids and lower acetate concentrations than RUM lambs (all P < 0.05). Plasma insulin-like growth factor concentrations were similar in both. The administration of bST raised plasma insulin-like growth factor-1 (P < 0.001) and insulin (P < 0.05) in MF and RUM lambs, but with greater effect in MF lambs (P < 0.01 and P < 0.1, respectively). Six successive dose-incremented insulin challenges (50, 100, 200, 300, 500, and 700 mU/kg body weight) were performed two per day on Days 8, 9, and 10 of treatment. Dose-response curves for absolute decline in glucose concentration from preinjection baseline to nadir were used to characterize whole-body responsiveness and sensitivity (ED50) to insulin. Somatotropin treatment increased insulin ED50 values 64 and 70% (P < 0.07) in RUM and MF lambs, respectively, suggesting that sensitivity to insulin was reduced. Insulin ED50 values were 40% higher in MF than in RUM lambs (P < 0.05). Insulin clearance rates increased with each dose increment to 300 mU/kg body weight (P = 0.001) and were 50% lower in bST-treated MF lambs than in all other treatment groups (P < 0.05). Results suggest that somatotropin modulates the insulin control of glucose homeostasis similarly in preruminant and ruminant lambs by decreasing sensitivity but not maximum responsiveness.
Bellver
S P
SP
Department of Animal Science, Cornell University, Ithaca, NY 14853, USA.
Beermann
D H
DH
Bell
A W
AW
Van Tassell
C P
CP
Hogue
D E
DE
McLaughlin
C L
CL
D000375:Aging / Q000097:blood / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000032:analysis*; D001806:Blood Urea Nitrogen; D004305:Dose-Response Relationship, Drug; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000378:metabolism; D013006:Growth Hormone / Q000494:pharmacology*; D006706:Homeostasis / Q000502:physiology; D007328:Insulin / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D008297:Male; D012417:Rumen / Q000187:drug effects / Q000502:physiology*; D012756:Sheep / Q000254:growth & development / Q000378:metabolism*
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D013006:Growth Hormone; D005947:Glucose; C108583:sometribove